HDAC Inhibition Induces Increased Choline Uptake and Elevated Phosphocholine Levels in MCF7 Breast Cancer Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Ward, Christopher S ^a   Eriksson, Pia ^a   Izquierdo Garcia, Jose L ^a   Brandes, Alissa H ^a   Ronen, Sabrina M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CHOLINE KINASE; CHOLINE KINASE ALPHA; CHOLINE TRANSPORTER SLC44A1; CYTIDYLYLTRANSFERASE; GLYCEROPHOSPHORYLCHOLINE; MEMBRANE PROTEIN; MESSENGER RNA; PHOSPHOLIPASE A2; PHOSPHORYLCHOLINE; TRANSFERASE; UNCLASSIFIED DRUG; VORINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN MCF 7; CHOLINE UPTAKE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METABOLITE; MICROARRAY ANALYSIS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PLA2 GENE; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SLC44A1 GENE; UPREGULATION; WESTERN BLOTTING; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLINE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GLYCERYLPHOSPHORYLCHOLINE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MAGNETIC RESONANCE SPECTROSCOPY; MCF-7 CELLS; PHOSPHORYLCHOLINE;

EID: 84876526317     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062610     Document Type: Article

References (45)

1. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, et al. (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193.
2. Xu WS, Parmigiani RB, Marks PA, (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552.
3. Lane AA, Chabner BA, (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468.
4. Mai A, Massa S, Rotili D, Cerbara I, Valente S, et al. (2005) Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25: 261-309.
5. Hess-Stumpp H, (2005) Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 84: 109-121.
6. Epping MT, Bernards R, (2009) Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. Int J Biochem Cell Biol 41: 16-20.
7. Glaser KB, (2007) HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74: 659-671.
8. Prince HM, Bishton MJ, Harrison SJ, (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15: 3958-3969.
9. Marks PA, Richon VM, Rifkind RA, (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216.
10. Stimson L, La Thangue NB, (2009) Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 280: 177-183.
11. de Certaines JD, Larsen VA, Podo F, Carpinelli G, Briot O, et al. (1993) In vivo 31P MRS of experimental tumours. NMR Biomed 6: 345-365.
12. Leach MO, Verrill M, Glaholm J, Smith TA, Collins DJ, et al. (1998) Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed 11: 314-340.
13. Kvistad KA, Bakken IJ, Gribbestad IS, Ehrnholm B, Lundgren S, et al. (1999) Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 10: 159-164.
14. Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, et al. (2000) Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2: 152-165.
15. Ronen SM, Jackson LE, Beloueche M, Leach MO, (2001) Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 84: 691-696.
16. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, et al. (2003) Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst 95: 1624-1633.
17. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Eccles SA, Raynaud FI, et al. (2006) Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol Cancer Ther 5: 187-196.
18. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, et al. (2005) Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res 65: 3356-3363.
19. Ross J, Najjar AM, Sankaranarayanapillai M, Tong WP, Kaluarachchi K, et al. (2008) Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine. Mol Cancer Ther 7: 2556-2565.
20. Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, et al. (2010) Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res 70: 1296-1305.
21. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, et al. (2010) Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 12: 559-569.
22. Sankaranarayanapillai M, Tong WP, Maxwell DS, Pal A, Pang J, et al. (2006) Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Mol Cancer Ther 5: 1325-1334.
23. Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, et al. (2008) Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia 10: 303-313.
24. Beloueche-Babari M, Arunan V, Troy H, te Poele RH, te Fong AC, et al. (2012) Histone deacetylase inhibition increases levels of choline kinase alpha and phosphocholine facilitating noninvasive imaging in human cancers. Cancer Res 72: 990-1000.
25. Beloueche-Babari M, Chung YL, Al-Saffar NM, Falck-Miniotis M, Leach MO, (2010) Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy. Br J Cancer 102: 1-7.
26. Negendank W, (1992) Studies of human tumors by MRS: a review. NMR Biomed 5: 303-324.
27. Podo F, (1999) Tumour phospholipid metabolism. NMR Biomed 12: 413-439.
28. Milkevitch M, Shim H, Pilatus U, Pickup S, Wehrle JP, et al. (2005) Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. Biochim Biophys Acta 1734: 1-12.
29. Brandes AH, Ward CS, Ronen SM, (2010) 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2. Breast Cancer Res 12: R84.
30. Tyagi RK, Azrad A, Degani H, Salomon Y, (1996) Simultaneous extraction of cellular lipids and water-soluble metabolites: evaluation by NMR spectroscopy. Magn Reson Med 35: 194-200.
31. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, et al. (2005) Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 65: 9369-9376.
32. Gabellieri C, Beloueche-Babari M, Jamin Y, Payne GS, Leach MO, et al. (2009) Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR. NMR Biomed 22: 456-461.
33. Katz-Brull R, Degani H, (1996) Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 16: 1375-1380.
34. Glunde K, Bhujwalla ZM, Ronen SM, (2011) Choline metabolism in malignant transformation. Nat Rev Cancer 11: 835-848.
35. Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY, et al. (2011) Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Res Treat 125: 55-63.
36. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, et al. (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104: 1828-1835.
37. Michel V, Yuan Z, Ramsubir S, Bakovic M, (2006) Choline transport for phospholipid synthesis. Exp Biol Med (Maywood) 231: 490-504.
38. Gallego-Ortega D, Gomez del Pulgar T, Valdes-Mora F, Cebrian A, Lacal JC, (2011) Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions. Adv Enzyme Regul 51: 183-194.
39. Eliyahu G, Kreizman T, Degani H, (2007) Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer 120: 1721-1730.
40. Sankaranarayanapillai M, Tong WP, Yuan Q, Bankson JA, Dafni H, et al. (2008) Monitoring histone deacetylase inhibition in vivo: noninvasive magnetic resonance spectroscopy method. Mol Imaging 7: 92-100.
41. Glunde K, Jie C, Bhujwalla ZM, (2004) Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 64: 4270-4276.
42. Yuan Z, Tie A, Tarnopolsky M, Bakovic M, (2006) Genomic organization, promoter activity, and expression of the human choline transporter-like protein 1. Physiol Genomics 26: 76-90.
43. Banchio C, Lingrell S, Vance DE, (2006) Role of histone deacetylase in the expression of CTP:phosphocholine cytidylyltransferase alpha. J Biol Chem 281: 10010-10015.
44. Sugimoto H, Banchio C, Vance DE, (2008) Transcriptional regulation of phosphatidylcholine biosynthesis. Prog Lipid Res 47: 204-220.
45. Geilen CC, Wieder T, Boremski S, Wieprecht M, Orfanos CE, (1996) c-Ha-ras oncogene expression increases choline uptake, CTP: phosphocholine cytidylyltransferase activity and phosphatidylcholine biosynthesis in the immortalized human keratinocyte cell line HaCaT. Biochim Biophys Acta 1299: 299-305.